Phase 1–3 cross-cultural development and pre-testing of the European Organisation of Research and Treatment of Cancer Vulva cancer questionnaire module (EORTC QLQ- VU)
OBJECTIVE: The aim of the study was to develop and pre-test a quality of life (QOL) measure for vulva cancer (VC) patients to supplement the EORTC QLQ-C30 core questionnaire. The overall purpose was to ensure content validity and to identify and solve potential conceptual and operational problems to ensure broad cross-cultural adaptation. METHODS: According to EORTC guidelines, a list of QOL issues relevant to VC patients undergoing surgery and/or chemo-radiotherapy was generated from a systematic literature review. The issue list underwent critical appraisal and revision by the EORTC QOL gynecological steering group (GSG). Semi-structured interviews followed patients' and health care professionals' scoring and priority rating to include issues of highest relevance and priority. The issues were operationalized into a provisional questionnaire that underwent pre-testing. RESULTS: An initial list of 104 issues was critically appraised by 25 members of the EORTC Gynecological Cancer Group and scored for relevance and priority by 47 patients and a further 18 HCPs with broad cross-country distribution. Based on pre-determined selection criteria, seven domains were retained for operationalization. The provisional questionnaire, the EORTC QLQ-VU consisted of 36 items and was pre-tested including debriefing in 77 patients, well-balanced across 12 centers in nine European countries. The pre-test resulted in deletion (4 items), re-phrasing (4 items), conditionality (5 items), and adding of two clarifying items. Patients' feedback resulted in significant changes enhancing patient acceptance and applicability. CONCLUSION: Cross-cultural pre-testing of the preliminary EORTC QLQ-VU demonstrates high relevance, applicability, and comprehensiveness for phases 1-3. Phase 4 psychometric validation is in progress.
Authors
- Hilde Toelen
- Samantha Serpentini (ORCID: https://orcid.org/0000-0002-0517-3416)
- Vesna Bjelic‐Radisic (ORCID: https://orcid.org/0000-0002-3749-4775)
- Ingvild Vistad (ORCID: https://orcid.org/0000-0002-5262-6326)
- Ligita Paskeviciute Froeding
- Claudia Schmalz (ORCID: https://orcid.org/0000-0002-7950-5647)
- Violante Di Donato (ORCID: https://orcid.org/0000-0002-9254-5790)
- Sara Dehandschutter
- Iwona M. Tomaszewska (ORCID: https://orcid.org/0000-0003-0952-5674)
- Eva Greimel
- Pernille T. Jensen
- Karin Kuljanić
- Samantha C. Sodergren (ORCID: https://orcid.org/0000-0001-8755-146X)
- Andy Nordin
- Eleonora Van Dorst
- Anne Oberguggenberger
- Razvan Galalae
- Anne Lanceley
- Lotte Vanden Boer
Institutions
- Jagiellonian University (PL)
- University College Hospital (GB)
- Innsbruck Medical University (AT)
- University of Rijeka (HR)
- Medical University of Graz (AT)
- Universitair Ziekenhuis Leuven (BE)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- East Kent Hospitals University NHS Foundation Trust (GB)
- Christian-Albrechts-Universität zu Kiel (DE)
- Istituto Oncologico Veneto (IT)
- Oncode Institute (NL)
- Helios Universitätsklinikum Wuppertal (DE)
- Klinikum Bremerhaven-Reinkenheide (DE)
- Sørlandet Sykehus (NO)
- University of Southampton (GB)
- University College London (GB)
- Sapienza University of Rome (IT)
- KU Leuven (BE)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2026-07-23
- DOI
- https://doi.org/10.1016/j.ygyno.2026.07.014
- Primary Topic
- Cancer survivorship and care
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Organisation for Research and Treatment of Cancer